Fig. 3. Time to response (days) in 8 patients with refractory warm autoimmune hemolytic anemia treated with rituximab at 100 mg/wk/4 weeks (A). Maintained response (MR) probability in 6 patients with refractory w-AIHA treated with rituximab at 100 mg/wk/4 weeks (B). Two patients were excluded because MR was less than 6 months.